OverviewChartProfileKey statisticsFinancialsNewsTraderScreen

IDORSIA LTD/  CH0363463438  /

Turquoise
2024-05-03  4:26:08 PM Chg. -0.02 Volume Bid- Ask- Market Capitalization Dividend Y. P/E Ratio
2.01CHF -0.79% 3,481
Turnover: 6,944.45		 -Bid Size: - -Ask Size: - -CHF - -
GlobeNewswire 04-17 Nxera Pharma: Notice of Issuance of New Shares Under the Restricted Stock Unit (RSU) Plan and Determ...
GlobeNewswire 04-01 Nxera Pharma is the New Name for Sosei Group
GlobeNewswire 03-27 Sosei Heptares Confirms Re-election of its Board and Executive Management Team and the Approval of C...
GlobeNewswire 02-28 Idorsia and Viatris enter into a significant global research and development collaboration
GlobeNewswire 02-16 Sosei Group: Notice of Change of Corporate Name to Nxera Pharma and Change of Location of Head Offic...
GlobeNewswire 02-13 Sosei Heptares Operational Highlights and Consolidated Results for 12 Months ended 31 December 2023
GlobeNewswire 01-22 Sosei Heptares Webinar Presentation for FY2023 Financial Results
GlobeNewswire 01-05 Sosei Group Announces Appointment of Experienced Pharmaceutical Executive Toshihiro Maeda as Chief O...
GlobeNewswire 2023-12-07 Sosei Group Announces Marketing Approval for PIVLAZ™ (clazosentan sodium) 150 mg in South Korea
GlobeNewswire 2023-11-15 Pharvaris Appoints Stefan Abele, Ph.D., as Chief Technical Operations Officer
GlobeNewswire 2023-11-10 Sosei Heptares Operational Highlights and Consolidated Results for the Third Quarter and First Nine ...
GlobeNewswire 2023-11-03 New Phase 3 data with aprocitentan for patients with resistant hypertension has been presented at th...
GlobeNewswire 2023-10-31 Sosei Heptares Announces Submission of New Drug Application in Japan for Daridorexant (ACT-541468), ...
GlobeNewswire 2023-10-25 Sosei Heptares to Host R&D Day Highlighting its Innovative R&D and Late-Stage Development Progress
GlobeNewswire 2023-10-16 CRISPR Therapeutics Proposes New Appointment to the Board of Directors
GlobeNewswire 2023-09-11 Oculis Expands its Executive Leadership Team and Appoints Rebecca Weil, Ph.D. as Chief Commercial Of...
GlobeNewswire 2022-02-28 Antares Pharma to Present at the Cowen 42nd Annual Healthcare Conference
GlobeNewswire 2022-02-17 Antares Pharma To Report Fourth Quarter And Full-Year 2021 Financial And Operating Results
GlobeNewswire 2022-02-08 Idorsia announces financial results for 2021 – 2022 to be a transformative year – Sustainable profit...
GlobeNewswire 2022-02-03 Nox Health Announces New Chief Marketing Officer, SVP of Content and VP of Security
GlobeNewswire 2022-02-03 Antares Pharma Announces FDA Acceptance of NDA Resubmission for TLANDO®
GlobeNewswire 2022-01-26 Idorsia expands its commercialization partnership with Syneos Health for daridorexant in Europe and ...
GlobeNewswire 2022-01-18 Antares Pharma Receives FDA Fast Track Designation for ATRS-1902 for Adrenal Crisis Rescue
GlobeNewswire 2022-01-11 Antares Pharma Announces Positive Results From Phase I Study For ATRS-1902 For Adrenal Crisis Rescue
GlobeNewswire 2022-01-10 Idorsia presents at the 40th J.P. Morgan Healthcare Conference – Ready for first product launches – ...